Healthcare

Cosmos Health Intends to Resume Share Repurchases as Insiders Agree to 12-Month Lock-Up

Cosmos Health plans to resume open-market share repurchases, with approximately $3.85 million remaining under its authorised programme. Company executives and directors have also agreed to a 12-month lock-up on shares they hold.

Published:
Reading Time
2 min

Cosmos Health Inc. (NASDAQ:COSM) said on November 19, 2026, that it intends to restart open-market purchases of its common stock under a $5.0 million repurchase programme. At the same time, the company’s executive officers and Board of Directors members have agreed not to sell or otherwise dispose of the shares they hold for 12 months.

The announcement describes two separate actions: a planned resumption of company share purchases and a lock-up commitment covering shares held by senior leadership and directors.

#Repurchase programme details

The programme was authorised by Cosmos Health’s Board of Directors on June 26, 2026. The company said it has so far repurchased 255,600 shares, or 5,112,000 pre-split, for approximately $1.15 million. Approximately $3.85 million remains available under the programme.

Any further purchases may take place from time to time in the open market and must comply with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Cosmos Health said the timing and amount of repurchases will depend on market conditions and other factors. The programme may also be suspended or discontinued at any time.

#12-month insider lock-up

Cosmos Health said its executive officers and Board members have agreed to retain the common stock they hold for 12 months, subject to the terms of their commitment. During that period, they have agreed not to sell or otherwise dispose of those shares.

The company identified Greg Siokas as its chief executive officer. In comments accompanying the announcement, Siokas cited the company’s strengthened balance sheet, record nine-month revenue and new growth engines, including an expanding subscription model. He said Cosmos Health believes it is well positioned, while the release also noted that forward-looking statements involve risks and uncertainties.

#Company background

Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. Its activities include pharmaceutical and nutraceutical brands, manufacturing through Cana Laboratories S.A., distribution of pharmaceuticals and parapharmaceuticals in Greece and the UK, research and development, and telehealth operations through ZipDoctor, Inc.

The company said it is expanding across Europe, Asia and North America. It has offices and distribution centres in Thessaloniki and Athens, Greece, and Harlow, UK.

#Key Takeaways

  • Cosmos Health intends to resume open-market repurchases under its $5.0 million programme.
  • Approximately $3.85 million remains available after repurchases of 255,600 shares, or 5,112,000 pre-split, for approximately $1.15 million.
  • Executive officers and Board members have agreed not to sell or otherwise dispose of the shares they hold for 12 months.
  • Repurchase timing and volume will depend on market conditions and other factors, and the programme may be suspended or discontinued at any time.

Original source: Read original article

Frequently Asked Questions